Pressreleases

Chemoswed Strengthens Organisation

As part of our continuing efforts to refine our organisation and improve our offering, we have created a new position, operations manager.

INFOTEHNA’s 14th Annual Pharmaceutical Conference: dynamic 3 days of learning, networking and valuable insights

INFOTEHNA’s annual pharmaceutical conference is the showpiece pharmacy event as it addresses current issues and challenges in pharmaceutical industry and provides attendees with valuable insights into solutions that will help conquer them. The conference also provides participants an opportunity to share their experiences with other professionals and experts.

Hybrigenics wins a USD 2.1 million yeast two-hybrid contract

Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments and specialised in protein interactions, today announces the signature of a 3-year research services agreement worth USD 2.1 million with an US multinational life sciences company.

Hybrigenics Services signs a master agreement with L’Oreal

Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments and specialised in protein interactions, today announces the signature of an openended master agreement between its fully-owned subsidiary, Hybrigenics Services SAS, and L’Oreal.

Hybrigenics SA brings its fee-for-service activities

Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments and specialised in protein interactions, today announces that its fee-for-service scientific activities are brought to a fully-owned subsidiary named Hybrigenics Services SAS (“Société Anonyme Simplifiée”).

Hybrigenics revenues grew 45% to EUR 6.6 million in 2011

Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases and specialized in protein interaction services, today announces its revenues and cash position for the year ended December 31st, 2011

Hybrigenics 2010 Revenues and Cash Position

Hybrigenics (ALHYG), a bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialized in protein interaction services, today announces its revenues and cash position for the year ended 31 December 2010.

Spectrum Announces TCI America Distribution Agreement

Spectrum Chemicals & Laboratory Products announces a new chemicals distribution
agreement with TCI America making Spectrum a premier US distributor of over 22,000 unique chemicals for research and science.

DEC MicroJet 10: Ideal for Pre-Clinical Trials and NCE Product Development

Following the success of the introduction of our award winning MCOne, Interphex 2011 New York saw the launch of Dec's New 4th Generation of Patented Jet Mills MicroJet including the launch of the world's smallest fully functioning jet mill, the DEC MicroJet 10.